Amphastar Pharmaceuticals (AMPH) Gross Margin (2016 - 2025)
Historic Gross Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to 51.42%.
- Amphastar Pharmaceuticals' Gross Margin fell 18900.0% to 51.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 49.36%, marking a year-over-year decrease of 36200.0%. This contributed to the annual value of 51.08% for FY2024, which is 34100.0% down from last year.
- According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Gross Margin is 51.42%, which was down 18900.0% from 49.59% recorded in Q2 2025.
- Amphastar Pharmaceuticals' 5-year Gross Margin high stood at 60.04% for Q3 2023, and its period low was 43.63% during Q1 2021.
- Its 5-year average for Gross Margin is 50.19%, with a median of 49.99% in 2025.
- As far as peak fluctuations go, Amphastar Pharmaceuticals' Gross Margin soared by 113300bps in 2023, and later crashed by -75300bps in 2024.
- Over the past 5 years, Amphastar Pharmaceuticals' Gross Margin (Quarter) stood at 46.52% in 2021, then increased by 13bps to 52.71% in 2022, then grew by 2bps to 53.98% in 2023, then dropped by -14bps to 46.45% in 2024, then increased by 11bps to 51.42% in 2025.
- Its Gross Margin stands at 51.42% for Q3 2025, versus 49.59% for Q2 2025 and 49.99% for Q1 2025.